Page 850 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

828 Index

Lipiodol, as chemoembolization, 178 Lymphocyte T-cell immunomodulator Lymphoma (Continued)
(LTCI), 24
Lipoma, 407 Lymphocytic leukemia, canine, 712–715 thrombocytosis and, 104
characteristics of, 139
waste sites and, 92
VetBooks.ir Lipoma, intermuscular, 407f acute, treatment of, 715 Lymphoreticular cell, 64t
fine-needle aspiration of, 139f
chronic, treatment of, 715
Liposarcoma, 405t, 408, 408f diagnostics and clinical staging, 714 M
fine-needle aspiration of, 139f history and clinical signs, 714 M phase, 182
histochemical stains for, 71t incidence, risk factors, and etiology, MAb. see Monoclonal antibody
Kaplan-Meier survival curve of, 408f 712–713 MAC. see Minimum alveolar concentration
prognosis for, 408 pathology and classification, 713, 714f Macrophage lineage, histiocytic sarcomas of,
Liposome, gene delivery and, 251–253 prognosis, 715 144
Liposome-DNA complex, 237 Lymphokine-activated kill cell transfer, 242 Magenta cytoplasmic inclusion, 133
Liposome/DNA conjugate, 252t Lymphoma, 18 Magnetic field, 16
Liposome-encapsulated muramyl tripeptide, canine, 688–711, 689b Magnetic resonance imaging (MRI), 117–118
236 classification and pathology, 689–693, for adrenal gland neoplasia, 572
Liposome-encapsulated muramyl tripeptide- 690f in hyperadrenocorticism, 566
phosphatidylethanolamine (L-MTP-PE), clinical staging, 701–702 MAHA. see Microangiopathic hemolytic
544 diagnostics, 696–701, 696t anemia
Lipoxygenase, 308f etiology, 688–689 Maintenance energy requirement (MER),
Liquid tumor, 63 extranodal, treatment of, 710–711 304t
Liver embolization, of interventional history and clinical signs, 693–696, Maintenance therapy, 183
oncology, 178, 178f 693b, 694f–695f Maitake mushroom, 332
Liver lobectomy, 458, 458f prognosis, 711, 712t–713t, 713f Malassezia-associated dermatitis, 105
Liver tumor, 287t reinduction and rescue chemotherapy, Male reproductive system tumor, 626–644
LLLT. see Low-level laser therapy 707–709, 707t–709t Malignancy
Lobaplatin, for canine osteosarcoma, 543t strategies to enhance effectiveness of criteria of, 131
Lobular orbital adenomas, 683 therapy in, 709 hemangiosarcoma with criteria of, 131f
Lomustine, 191 treatment approaches using immunologic oncogene mutations/chromosomal
metronomic chemotherapy protocol with, or biologic agents, 709–710 abnormalities and, 146
267 treatment of multicentric lymphoma, paraneoplastic syndromes and, 98
Longitudinal bone transport osteogenesis 702–707 receptor tyrosine kinases and, 258f
(BTO), for canine osteosarcoma, chemotherapy and remission of, 190f Malignant bone marrow disorder, 263
537–538, 538f diagnosis of, 142–143 Malignant canine mammary neoplasms,
Long-term enteral support, 304–305 2,4-dichlorophenoxyacetic acid (2,4-D), 608–610
Loss and grief, providing support for, 318 15, 92 carcinosarcoma (malignant mixed
Low-dose dexamethasone suppression test environmental tobacco smoke and, 92 mammary tumor), 609
(LDDST), in hyperadrenocorticism, 566 features of importance and grades for, 68t grading of, 609–610
Low-level laser therapy (LLLT), 336 feline, 715–718, 716b hyperplasia/dysplasia/neoplasia of nipple,
LTCI. see Lymphocyte T-cell chronic inflammation, 718 609
immunomodulator diet and intestinal lymphoma, 718 malignant epithelial tumors, 608, 609t
Lung cancer environmental factors, 717 prognostic factors of, 609–610
colony formation and, 50 etiology, 716–718 sarcomas, 608
environmental tobacco smoke and, 14 genetic and molecular factors, 717 Malignant epithelial tumors, 652
pain caused by, 287t immunosuppression, 717–718 canine, 608, 609t
177 Lutetium ( 177 Lu), 548 incidence, 715–716 Malignant fibrous histiocytoma, 406
Lycopene, 309 pathology and natural behavior, 718 Malignant histiocytosis (MH)
Lymph node viral factors, 716–717, 717t cell characteristics in, 144
assessment of, 121–122 feline immunodeficiency virus and, 93 tumor suppressor gene loss and, 147
metastasis, 66–67 feline leukemia virus and, 23–24 Malignant melanoma
metastatic lesions identification in, 141 fine-needle aspiration of lymph node with, cell characteristics in, 141
removal of, 168 128f of digit, 361, 362f
Lymphadenectomy, 369 FIV infection and, 25 in digital webbing
for apocrine gland anal sac adenocarcinoma, hypercalcemia of malignancy and, 100 excisional biopsy of, 369f
470–476 immunohistochemical markers/panels for, surgical margins for, 371f
Lymphangiosarcoma, 405t 72t–73t of oral cavity, 432
immunohistochemical markers/panels for, in intestinal tumors, 461 prognosis of, 440–442, 441t
72t–73t intraocular, 682–683 surgical margin for, 370
Lymphatic tissue, tumors of, 408–409 paraneoplastic syndromes and, 100 Malignant mesenchymoma, 409–410
Lymphatics, tumor microenvironment and, phenoxy acid-containing herbicide and, 92 Malignant mixed mammary tumor, 609
263 smoking and, 14 Malignant pilomatricoma, 359
Lymphocyte, view of, 131f in spinal cord, 666t Malignant transformation, 16
Lymphocyte-activation gene 3 (Lag3), 233 survival rate with, body condition and, 301 Malignant trichoepithelioma, 359